Lysosomal membrane permeabilization is involved in CYP2E1-induced apoptosis in hepatocellular carcinoma cells Authors: Xuan Wang, An Wang, Huanhuan He, Jiaqi Qiao, Chengyi Wang, Haiyuan Du, Xiji Shu, Binlian Sun, Xiaoqing Chen, Qiongxia Chen, Xuan Huang, Shaobo Hu, Yuchen Liu, Zhengqi Fu Published: 2026 ABSTRACT Highlights•CYP2E1 overexpression induces LMP and subsequent apoptosis in HCC cells.•CYP2E1 upregulates NEU4, causing deglycosylation and degradation of LAMP1/2.•Low CYP2E1 in HCC patients correlates with high LAMP1/2 glycosylation. Introduction Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a poor survival rate [1]. When first diagnosed, most HCC patients are often at advanced stages with limited therapeutic options. Thus, it is urgent to identify novel targets and understand their roles in HCC development. Cytochrome P450 2E1 (CYP2E1) is a key hepatic metabolic enzyme involved in the metabolism of numerous xenobiotics and procarcinogens [2,3]. Recent studies have demonstrated that CYP2E1 plays an etiological role in HCC occurrence and development [4]. Clinically, decreased CYP2E1 expression in HCC tumor tissues correlates with aggressive tumor type and poor prognosis of HCC patients [5,6]. In the HCC models of rat, CYP2E1 expression gradually declines with worsening liver lesions and cirrhosis, becoming nearly undetectable in advanced HCC [7,8]. Reversely, CYP2E1 overexpression is able to suppress malignant growth of HCC cells both in vitro and in vivo [9]. These results suggest that CYP2E1 expression is negatively associated with HCC progression, warranting further investigations into its function and the underlying mechanism. Accumulating evidence has demonstrated the critical role of lysosome in maintaining cell homeostasis. Lysosomal alterations including changes in number, size, acidification and cathepsin activity, are commonly observed in tumor cells, suggesting the increased metabolic demands for tumor cell growth and stress adaption. However, such lysosomal changes and dysfunctions also reduce the integrity and stability of lysosomal membranes, making tumor cells more susceptible to lysosomal membrane permeabilization (LMP) [10]. LMP is a process that the lysosome loses its membrane integrity and releases lysosomal hydrolases into the cytosol, resulting in various forms of cell death, such as apoptosis, necrosis, ferroptosis, pyroptosis, and lysosome-dependent cell death (LDCD) [11]. Thus, lysosomes are increasingly recognized as pivotal regulators of cell fate. Nevertheless, the functional regulation of lysosomes in tumor biology remains incompletely understood. Notably, lysosomes lack antioxidant enzymes such as superoxide dismutase, making their membrane particularly vulnerable to damage caused by reactive oxygen species (ROS) [12,13]. CYP2E1 is a key source of ROS which is a known inducer of LMP, however, whether and how CYP2E1 contributes to the inhibition of HCC cells through lysosomal regulation remains unclear, and a direct link between CYP2E1 and lysosomal function in HCC is lacking. Given the pivotal role of CYP2E1 in inducing apoptosis and the significant pro-apoptotic therapeutic potential of LMP, both of which are critically involved in the pathogenesis and progression of HCC, we hypothesized that CYP2E1 overexpression triggers LMP, thereby promoting apoptosis in HCC cells. To test this hypothesis, we examined LMP, cathepsin D release and lysosome-associated membrane proteins 1 and 2 (LAMP1/2) stability in CYP2E1-overexpressing HCC cell lines and xenograft models. Additionally, we assessed the expression levels of CYP2E1, LAMP1 and LAMP2 in the tumor tissues from HCC patients to evaluate clinical relevance. Materials and methods Chemicals and antibodies The antibodies against CYP2E1 (19,937-1-AP), NEU4 (12,995-1-AP), LGALS3/Galectin-3 (Gal-3) (60,207-1-Ig), LAMP1 (67,300-1-Ig), LAMP2 (66,301-1-Ig), Cathepsin D (CTSD) (21,327-1-AP), Caspase-3(19,677-1-AP) and β-actin (60,009-1-IG) were purchased from Proteintech Group (Rosemont, IL, USA). The antibody of Cleaved Caspase-3 (341,034) was purchased from Zenbio (Chengdu, China). Cycloheximide (CHX) (HY-12,320) and Pepstatin A (Pep A) (HY-P0018) were obtained from MedChemExpress (New Jersey, USA). ABflo® 488-conjugated Goat anti-mouse IgG (H + L) (AS076) was from ABclonal Technology (Wuhan, China). Lyso-Tracker Red (C1046) and Hoechst 33,342 (C1028) were from Beyotime Biotechnology (Nanjing, China). Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA). Fetal Bovine Serum (FBS) was from Sijiqing (Hangzhou, China). Small interfering RNAs (siRNAs) targeting NEU4 were purchased from OBiO (Shanghai, China). The sequences of the siRNA oligos used are as follows: si-Ctrl: 5′-UUC UCC GAA CGU GUC ACG UTT-3′; si-NEU4#1: 5′-CAC GGA CAG UGC UCU UCG ATT-3′. Clinical tumor samples All human samples were used after written and informed consent of patients and approval of the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (2019 IEC (S646)). HCC cancerous and para-cancerous tissues were obtained from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between May 2019 and December 2023. The samples were from twenty-four men and six women aged 42–78 years (mean 61.7 years), and none of them had received any anticancer treatment before surgery. Cell culture and stable cell lines Human HCC HepG2 and Huh7 cell lines were obtained from Shenogen Pharma Group (Beijing, China), and maintained in DMEM with 10% FBS at 37 °C in a humidified incubator with 5% CO2. Stable CYP2E1 expression (HepG2/CYP2E1 and Huh7/CYP2E1) cell lines and their control (HepG2/Vector and Huh7/Vector) cell lines were generated by stable transfection of pcDNA-CYP2E1 and pcDNA empty vector (Fenghui Biotechnology Co., LTD), as described before [6]. CYP2E1 expression in these stable cell lines were verified by Western blot analysis. Lysosome preparation Lysosomes were isolated using a Lysosome Enrichment Kit (Bestbio, Shanghai, China). briefly, PBS-washed cells were resuspended in Reagent A, incubated on ice for 10 min, and homogenized. After centrifugation at 1000 × g for 5 min at 4 °C, the supernatant was sequentially centrifuged at 3000 × g for 10 min, 5000 × g for 10 min, and 20,000 × g for 20 min. The supernatant was collected and labeled as cytosolic fraction. The pellets were suspended in Reagent B, re-centrifuged (20,000 × g, 20 min), and the final pellets were resuspended in Reagent C as the lysosome-enriched fraction. Deglycosylation using PNGase F Cell and tumor tissue lysates in radioimmunoprecipitation (RIPA) buffer were mixed with the Denaturing Buffer, heated, chilled briefly and centrifuged. The supernatants were then mixed with the Reaction Buffer, the Renaturing Buffer, ultrapure water, or PNGase F (500 U/µL, Beyotime Biotechnology, Nanjing, China) and incubated at 37 °C for 2 h. Finally, the samples were analyzed with Western blot analysis. Real-time quantitative PCR (RT-qPCR) RNA was extracted with the Ultrapure RNA Kit (CW0581M, Cowin Biotech, Jiangsu, China). For reverse transcription, 0.5 µg RNA was transcribed into cDNA using 5× Easy Quick RT MasterMix (CW2019M, Cowin Biotech, Jiangsu, China). RT-qPCR was performed using cDNA template mixed with SYBR Green mix (CW3008H, Cowin Biotech, Jiangsu, China), specific primers (Table 1) (20 µM each) and ultrapure water on a Bio-Rad thermal cycler (CA, USA).Table 1Real-time RT-qPCR primers.Table 1 dummy alt textHuman GAPDH-FAAGGCTGTGGGCAAGGHuman GAPDH-RTGGAGGAGTGGGTGTCGHuman LAMP1-FCCAGTTCGGGATGAATGCAAGTHuman LAMP1-RTTGGCAGCTTTAAAGGCAGGGTHuman LAMP2-FCGCCGATTCCTGGCTTTTGHuman LAMP2-RAAGAGCACTGATGACCACCG Table 1Real-time RT-qPCR primers.Table 1 dummy alt textHuman GAPDH-FAAGGCTGTGGGCAAGGHuman GAPDH-RTGGAGGAGTGGGTGTCGHuman LAMP1-FCCAGTTCGGGATGAATGCAAGTHuman LAMP1-RTTGGCAGCTTTAAAGGCAGGGTHuman LAMP2-FCGCCGATTCCTGGCTTTTGHuman LAMP2-RAAGAGCACTGATGACCACCG Real-time RT-qPCR primers. Western blot analysis Cells, lysosome fraction and liver tissues were lysed with the RIPA buffer supplemented with the protease and phosphatase inhibitors (Sigma, MO, USA). The protein concentrations were determined using the bicinchoninic acid kit (Bio-Rad, CA, USA). Equal amounts of proteins were separated on 10% SDS-PAGE gels, transferred to PVDF membranes that were blocked and probed with the indicated antibodies. Target proteins were detected by ECL Western-blot Analysis System. Animal experiments All animal-experimental procedures were performed as previously described in compliance with the National Institutes of Health guidelines on the ethical use of animals and approved by the Ethics Committee of Jianghan University (JHDXLL2024–005). Male BALB/c-nu mice (5 weeks old) were purchased from Beijing SiPeiFu Animal Technology Co. LTD and housed in specific pathogen-free conditions with the constant temperature (24 ± 2 °C) and relative humidity (60%). HepG2/CYP2E1 cells and HepG2/Vector cells (5 × 106 cells/mice) were injected into the liver of BALB/c-nu mice (n = 4) to establish orthotopic liver xenograft tumor model and maintained for 28 d After euthanasia, the livers were removed for further analysis. Immunofluorescence (IF) staining After fixing with 4% paraformaldehyde, the samples were incubated with the corresponding primary antibodies and Alexa Fluor conjugated secondary antibodies for IF staining, and nuclei were stained with Hoechst 33,342. Images were captured using a fluorescence microscope (Olympus, Tokyo, Japan). Hoechst 33342 staining Cells (5 × 104 cells) were seeded in 24-well plates, fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 20 min. and washed with PBS twice. Hoechst staining was then performed on the fixed cells using a Hoechst Staining Kit (P0133; Beyotime Biotechnology, China). Cell apoptotic features such as nuclear fragmentation and chromatin condensation were examined under a fluorescence microscope (Olympus, Tokyo, Japan) and photographed. Lyso-Tracker red staining Cells were seeded in 24-well plates, incubated in Lyso-Tracker Red (50 nM) at 37 °C for 15 min, and then incubated in Hoechst 33,324 at 37 °C for 10 min. Images were captured using a fluorescence microscope (Olympus, Tokyo, Japan). Immunohistochemistry (IHC) assay After deparaffinizing, rehydrating gradually by gradient alcohol and incubating in a 3% hydrogen peroxide/methanol buffer, the slides were immersed in an ethylenediamine tetra acetic acid buffer (pH 8.0) and boiled for 5 min. Then, the slides were washed and incubated with the indicated antibodies. Diaminobenzidine was used to generate signals, and images were captured. Gene and protein expression analysis UALCAN programs (https://ualcan.path.uab.edu/) was used to analyze the relative mRNA expression of LAMP1 and LAMP2 in the tumor and normal samples of HCC patients. Statistical analysis Data were presented as the mean ± standard error of mean (SEM) using a GraphPad Prim 8.0 software with analysis of variance (ANOVA), followed by Bonferroni's post hoc tests. A P-value <0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Results CYP2E1 overexpression induces LMP To investigate the role of CYP2E1 in lysosomal function, we established stable HCC cell lines overexpressing CYP2E1 (Fig. 1A–B). Lyso-Tracker Red staining revealed an increased lysosomal volume in HCC/CYP2E1 cells compared to HCC/Vector cells (Fig. 1C-D). A galectin-3 (Gal-3) puncta assay was then performed to detect LMP. Under normal conditions, Gal-3 is diffusely localized in the cytoplasm and nucleus, however, upon LMP, it rapidly translocates to damaged lysosomes and forms puncta. As shown in Fig. 1E, the HCC/CYP2E1 cells exhibited distinct Gal-3 puncta, whereas the HCC/Vector cells displayed a diffused pattern (Fig. 1E).Fig. 1CYP2E1 overexpression induces LMP and lysosomal damage. (A-B). HCC cells were stably transfected with pcDNA-CYP2E1 (HCC/CYP2E1) or pcDNA as an empty vector control (HCC/Vector), and the level of CYP2E1 was measured by Western blot analysis (A) and quantitatively analyzed (B). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0001, Huh7/Vector vs. Huh7/CYP2E1 group: ***P = 0.0003. (C-D). The HCC/CYP2E1 and HCC/Vector cells were stained with Lyso-Tracker Red and photographed under a fluorescence microscope . Representative images of lysosomal morphology in HCC/CYP2E1 and HCC/Vector cells were shown (C), and the lysosome diameter was measured and statistically analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ****P < 0.0001, Huh7/Vector vs. Huh7/CYP2E1 group: ****P < 0.0001. Scale bars, 20 µm. (E). The HCC/CYP2E1 and HCC/Vector cells were analyzed by immunofluorescence (IF) using the Gal‑3 antibody to monitor lysosomal membrane damage (E). Nuclei were stained with Hoechst 33342. Scale bar, 20 µm. (F-G). Indicated proteins in both lysosomal and cytoplasmic fractions extracted from the cells were detected by Western blot analysis (F) and quantitatively analyzed (G). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0042 (cytoplasmic), **P = 0.0011 (lysosomal). Huh7/Vector vs. Huh7/CYP2E1 group: **P = 0.0040 (cytoplasmic), **P = 0.0015 (lysosomal). The data represent the mean ± SEM.Fig 1 dummy alt text CYP2E1 overexpression induces LMP and lysosomal damage. (A-B). HCC cells were stably transfected with pcDNA-CYP2E1 (HCC/CYP2E1) or pcDNA as an empty vector control (HCC/Vector), and the level of CYP2E1 was measured by Western blot analysis (A) and quantitatively analyzed (B). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0001, Huh7/Vector vs. Huh7/CYP2E1 group: ***P = 0.0003. (C-D). The HCC/CYP2E1 and HCC/Vector cells were stained with Lyso-Tracker Red and photographed under a fluorescence microscope . Representative images of lysosomal morphology in HCC/CYP2E1 and HCC/Vector cells were shown (C), and the lysosome diameter was measured and statistically analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ****P < 0.0001, Huh7/Vector vs. Huh7/CYP2E1 group: ****P < 0.0001. Scale bars, 20 µm. (E). The HCC/CYP2E1 and HCC/Vector cells were analyzed by immunofluorescence (IF) using the Gal‑3 antibody to monitor lysosomal membrane damage (E). Nuclei were stained with Hoechst 33342. Scale bar, 20 µm. (F-G). Indicated proteins in both lysosomal and cytoplasmic fractions extracted from the cells were detected by Western blot analysis (F) and quantitatively analyzed (G). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0042 (cytoplasmic), **P = 0.0011 (lysosomal). Huh7/Vector vs. Huh7/CYP2E1 group: **P = 0.0040 (cytoplasmic), **P = 0.0015 (lysosomal). The data represent the mean ± SEM. LMP is usually accompanied by decreased LAMP1 expression and the release of lysosomal cathepsins like CTSD into the cytoplasm [14]. Western blot analysis of cytoplasmic and lysosome-enriched fractions showed that decreased CTSD levels in the lysosomal fraction and a corresponding increase in the cytoplasmic fraction of HCC/CYP2E1 cells (Fig. 1F–G). In addition, the expression levels of LAMP1 and LAMP2 were decreased in the HCC/CYP2E1 cells (Fig. 3B–D). These results suggest that CYP2E1 overexpression induces LMP in HCC cells, leading to the leakage of CTSD from the lysosomal lumen to the cytoplasm. The CTSD-dependent pathway is involved in CYP2E1 overexpression-induced apoptosis Since the leakage of lysosomal cathepsins into the cytosol may trigger apoptosis [15], we examined whether CTSD mediates CYP2E1-induced apoptosis. The HCC/CYP2E1 and HCC/Vector cells were treated with the CTSD inhibitor, Pepstatin A (Pep A). Hoechst dye staining showed that Pep A treatment significantly reversed CYP2E1 overexpression-induced apoptosis (Fig. 2A–B). Consistently, Western blot analysis revealed that Caspase-3 activation induced by CYP2E1 overexpression was markedly attenuated after Pep A treatment (Fig. 2C–D). These results indicate that CTSD is involved in CYP2E1 overexpression-induced apoptosis in HCC cells.Fig. 2CTSD is involved in cell apoptosis induced by CYP2E1 overexpression. The HCC/CYP2E1 and HCC/Vector cells were treated with Pep A (10 µM) for 16 h, and the same volume of DMSO was used as a vehicle control. (A-B). Cells were stained with Hoechst 33342, and representative images showing apoptotic morphological features (red arrows) were presented (A). The apoptotic rate was then quantified (B). HepG2/Vector vs. HepG2/CYP2E1 group: ****P < 0.0001; HepG2/CYP2E1: Vehicle vs. Pep A group: ****P < 0.0001. Huh7/Vector vs. Huh7/CYP2E1 group: ****P < 0.0001; Huh7/CYP2E1: Vehicle vs. Pep A group: ****P < 0.0001. Scale bar, 50 µm. (C-D). The levels of Cleaved Caspase-3/Caspase-3 ratio were assessed by Western blot analysis (C) and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0002; HepG2/CYP2E1: Vehicle vs. Pep A group: ***P = 0.0001. Huh7/Vector vs. Huh7/CYP2E1 group: ***P = 0.0004; Huh7/CYP2E1: Vehicle vs. Pep A group: **P = 0.0011. The data represent the mean ± SEM.Fig 2 dummy alt text CTSD is involved in cell apoptosis induced by CYP2E1 overexpression. The HCC/CYP2E1 and HCC/Vector cells were treated with Pep A (10 µM) for 16 h, and the same volume of DMSO was used as a vehicle control. (A-B). Cells were stained with Hoechst 33342, and representative images showing apoptotic morphological features (red arrows) were presented (A). The apoptotic rate was then quantified (B). HepG2/Vector vs. HepG2/CYP2E1 group: ****P < 0.0001; HepG2/CYP2E1: Vehicle vs. Pep A group: ****P < 0.0001. Huh7/Vector vs. Huh7/CYP2E1 group: ****P < 0.0001; Huh7/CYP2E1: Vehicle vs. Pep A group: ****P < 0.0001. Scale bar, 50 µm. (C-D). The levels of Cleaved Caspase-3/Caspase-3 ratio were assessed by Western blot analysis (C) and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0002; HepG2/CYP2E1: Vehicle vs. Pep A group: ***P = 0.0001. Huh7/Vector vs. Huh7/CYP2E1 group: ***P = 0.0004; Huh7/CYP2E1: Vehicle vs. Pep A group: **P = 0.0011. The data represent the mean ± SEM. CYP2E1 overexpression induces deglycosylation and degradation of LAMP1/2 LAMP1/2 are glycosylated transmembrane proteins that maintain lysosomal membrane integrity [16]. Although LAMP1 and LAMP2 mRNA levels showed no significant difference (Fig. 3A), their protein levels were markedly reduced in HCC/CYP2E1 cells compared to HCC/Vector controls (Fig. 3B–D). Notably, the molecular weights of LAMP1 and LAMP2 shifted from the typically 120–130 kDa (due to glycosylation) to approximately 70 kDa in HCC/CYP2E1 cells, suggesting that CYP2E1 overexpression may induce deglycosylation (Fig. 3B). A PNGase F digestion assay, which removes N-linked glycosylation, further demonstrated that in addition to protein deglycosylation, the protein expression levels of LAMP1 and LAMP2 were also decreased in HCC/CYP2E1 cells (Fig. 3C–D), indicating that deglycosylation may contribute to the reduction of LAMP1/2.Fig. 3CYP2E1 overexpression induces deglycosylation and degradation of LAMP1/2. (A-B). The mRNA and protein levels of LAMP1 and LAMP2 in the HCC/CYP2E1 and HCC/Vector cells were measured by RT-qPCR (A) and Western blot analysis (B). (C-D). Cell lysates were incubated with PNGase F at 37 °C for 2 h. The deglycosylated LAMP1 and LAMP2 were then analyzed by Western blot analysis (C) and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0002 (de-LAMP1), **P = 0.0012 (de-LAMP2). Huh7/Vector vs. Huh7/CYP2E1 group: **P = 0.0013 (de-LAMP1), ***P = 0.0005 (de-LAMP2). (E). HCC/CYP2E1 and HCC/Vector cells were incubated with CHX (50 µM) and harvested at 0, 4, 8, 12 and 24 h. The steady state levels of LAMP1 and LAMP2 were then evaluated by Western blot analysis (E). (F-G). The HCC/CYP2E1 cells were co-treated with CHX (50 µM) and Pep A (10 µM) or mock-treated for 8 h. The levels of LAMP1 and LAMP2 were measured by Western blot analysis (F) and quantitatively analyzed (G). HepG2/CYP2E1. LAMP1: ***P = 0.0002 (Vehicle vs. CHX), ***P = 0.0003 (CHX vs. CHX + Pep A); LAMP2: **P = 0.0011 (Vehicle vs. CHX), **P = 0.0012 (CHX vs. CHX + Pep A). Huh7/CYP2E1. LAMP1: ***P = 0.0002 (Vehicle vs. CHX), ***P = 0.0008 (CHX vs. CHX + Pep A); LAMP2: ***P = 0.0006 (Vehicle vs. CHX), **P = 0.0057 (CHX vs. CHX + Pep A). The data represent the mean ± SEM.Fig 3 dummy alt text CYP2E1 overexpression induces deglycosylation and degradation of LAMP1/2. (A-B). The mRNA and protein levels of LAMP1 and LAMP2 in the HCC/CYP2E1 and HCC/Vector cells were measured by RT-qPCR (A) and Western blot analysis (B). (C-D). Cell lysates were incubated with PNGase F at 37 °C for 2 h. The deglycosylated LAMP1 and LAMP2 were then analyzed by Western blot analysis (C) and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: ***P = 0.0002 (de-LAMP1), **P = 0.0012 (de-LAMP2). Huh7/Vector vs. Huh7/CYP2E1 group: **P = 0.0013 (de-LAMP1), ***P = 0.0005 (de-LAMP2). (E). HCC/CYP2E1 and HCC/Vector cells were incubated with CHX (50 µM) and harvested at 0, 4, 8, 12 and 24 h. The steady state levels of LAMP1 and LAMP2 were then evaluated by Western blot analysis (E). (F-G). The HCC/CYP2E1 cells were co-treated with CHX (50 µM) and Pep A (10 µM) or mock-treated for 8 h. The levels of LAMP1 and LAMP2 were measured by Western blot analysis (F) and quantitatively analyzed (G). HepG2/CYP2E1. LAMP1: ***P = 0.0002 (Vehicle vs. CHX), ***P = 0.0003 (CHX vs. CHX + Pep A); LAMP2: **P = 0.0011 (Vehicle vs. CHX), **P = 0.0012 (CHX vs. CHX + Pep A). Huh7/CYP2E1. LAMP1: ***P = 0.0002 (Vehicle vs. CHX), ***P = 0.0008 (CHX vs. CHX + Pep A); LAMP2: ***P = 0.0006 (Vehicle vs. CHX), **P = 0.0057 (CHX vs. CHX + Pep A). The data represent the mean ± SEM. Glycosylation is known to influence protein stability [17]. To determine whether the reduced LAMP1/2 expression results from enhanced post-transcriptional degradation, we treated HCC/CYP2E1 and the HCC/Vector cells with cycloheximide (CHX). Steady-state LAMP1/2 protein levels were decreased in the HCC/CYP2E1 cells treated with CHX over 8 h compared to those in the vehicle control cells (Fig. 3E), suggesting accelerated post-transcriptional degradation of LAMP1/2 in CYP2E1-overexpressing cells. To characterize the mechanism underlying this accelerated degradation, the decrease in LAMP1/2 protein was measured in HCC/CYP2E1 cells treated with CHX in combination with the cathepsin D inhibitor Pep A. We found that Pep A blocked CYP2E1 overexpression-induced LAMP1/2 protein instability (Fig. 3F–G), suggesting a potential involvement of CTSD. Taken together, these results indicate that CYP2E1 overexpression leads to deglycosylation and subsequent CTSD-dependent degradation of LAMP1/2. NEU4 is involved in CYP2E1 overexpression-induced LMP and apoptosis To explore the mechanism underlying CYP2E1 overexpression-induced deglycosylation of LAMP1/2, we examined the expression level of NEU4, a sialidase that hydrolyzes most oligosaccharides, glycoproteins and gangliosides [18]. Low NEU4 expression has been linked to poor prognosis in HCC patients [19]. Here, we found that NEU4 expression was increased in CYP2E1-overexpressing cells compared to the control cells (Fig. 4D–E). To determine whether NEU4 contributes to CYP2E1-induced LMP and apoptosis, we knocked down NEU4 in HCC/CYP2E1 cells using siRNA. NEU4 knockdown restored steady-state LAMP1/2 protein levels, and attenuated LMP and apoptosis in the HCC/CYP2E1 cells, as evidenced by a reduction of Gal-3 puncta (Fig. 4A), decreased apoptotic features in Hoechst dye staining (Fig. 4B–C) and the downregulated level of Cleaved Caspase-3 (Fig. 4D–E). These results indicate that NEU4 is involved in CYP2E1-induced LMP and apoptosis.Fig. 4NEU4 is involved in CYP2E1 overexpression-induced LMP and cell apoptosis. (A-C). The HCC/CYP2E1 and HCC/Vector cells transfected with si-NEU4 and si-Ctrl were analyzed by IF assay using the Gal‑3 antibody to monitor lysosomal membrane damage (A). These cells were stained with Hoechst 33342 to visualize apoptotic morphological features (B). Scale bar, 20 µm for Gal‑3 staining, and 50 µm for Hoechst staining. The apoptotic rate was quantified (C). HepG2/Vector + si-Ctrl vs. HepG2/CYP2E1 + si-Ctrl group: ****P < 0.0001; HepG2/CYP2E1: si-Ctrl vs. si-NEU4 group: ****P < 0.0001. Huh7/Vector + si-Ctrl vs. Huh7/CYP2E1 + si-Ctrl group: ****P < 0.0001; Huh7/CYP2E1: si-Ctrl vs. si-NEU4 group: ****P < 0.0001. (D-E) The levels of NEU4, LAMP1, LAMP2 and Cleaved Caspase-3/Caspase-3 ratio in the HCC/CYP2E1 and HCC/Vector cells transfected with si-NEU4 and si-Ctrl were measured by Western blot analysis (D) and quantitatively analyzed (E). HepG2/Vector + si-Ctrl vs. HepG2/CYP2E1 + si-Ctrl group: ***P = 0.0004 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio); HepG2/CYP2E1: si-Ctrl vs. si-NEU4 group: ***P = 0.0002 (NEU4), ***P = 0.0006 (Cleaved Caspase-3/Caspase-3 ratio). Huh7/Vector + si-Ctrl vs. Huh7/CYP2E1 + si-Ctrl group: **P = 0.0013 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio); Huh7/CYP2E1: si-Ctrl vs. si-NEU4 group: ***P = 0.0006 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio). The data represent the mean ± SEM.Fig 4 dummy alt text NEU4 is involved in CYP2E1 overexpression-induced LMP and cell apoptosis. (A-C). The HCC/CYP2E1 and HCC/Vector cells transfected with si-NEU4 and si-Ctrl were analyzed by IF assay using the Gal‑3 antibody to monitor lysosomal membrane damage (A). These cells were stained with Hoechst 33342 to visualize apoptotic morphological features (B). Scale bar, 20 µm for Gal‑3 staining, and 50 µm for Hoechst staining. The apoptotic rate was quantified (C). HepG2/Vector + si-Ctrl vs. HepG2/CYP2E1 + si-Ctrl group: ****P < 0.0001; HepG2/CYP2E1: si-Ctrl vs. si-NEU4 group: ****P < 0.0001. Huh7/Vector + si-Ctrl vs. Huh7/CYP2E1 + si-Ctrl group: ****P < 0.0001; Huh7/CYP2E1: si-Ctrl vs. si-NEU4 group: ****P < 0.0001. (D-E) The levels of NEU4, LAMP1, LAMP2 and Cleaved Caspase-3/Caspase-3 ratio in the HCC/CYP2E1 and HCC/Vector cells transfected with si-NEU4 and si-Ctrl were measured by Western blot analysis (D) and quantitatively analyzed (E). HepG2/Vector + si-Ctrl vs. HepG2/CYP2E1 + si-Ctrl group: ***P = 0.0004 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio); HepG2/CYP2E1: si-Ctrl vs. si-NEU4 group: ***P = 0.0002 (NEU4), ***P = 0.0006 (Cleaved Caspase-3/Caspase-3 ratio). Huh7/Vector + si-Ctrl vs. Huh7/CYP2E1 + si-Ctrl group: **P = 0.0013 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio); Huh7/CYP2E1: si-Ctrl vs. si-NEU4 group: ***P = 0.0006 (NEU4), ***P = 0.0002 (Cleaved Caspase-3/Caspase-3 ratio). The data represent the mean ± SEM. CYP2E1 overexpression induces LMP and apoptosis in vivo Our previous studies have shown that CYP2E1 overexpression inhibited the growth of HepG2 cells-derived tumors in nude mice [6]. To further confirm the in vivo role of CYP2E1 in LMP and apoptosis, xenograft tumors were analyzed by Western blot analysis, IHC and IF staining. Consistent with our in vitro findings, Western blot analysis and IHC staining revealed that tumors derived from HepG2/CYP2E1 cells exhibited increased levels of Cleaved Caspase-3 and NEU4 expression as well as decreased levels of LAMP1/2 and CTSD expression compared to HepG2/Vector cell-derived tumors (Fig. 5A–Fig. 5, Fig. 5). IF staining showed an increased number of Gal-3 puncta in HepG2/CYP2E1 cell-derived tumors (Fig. 5F). Furthermore, the identical band shift of LAMP1/2 to a lower molecular weight was observed in HepG2/CYP2E1 cell-derived tumors compared to controls, and PNGase F treatment demonstrated the shift to a non-glycosylated form (Fig. 5C–D). These results indicate that CYP2E1 overexpression induces LMP and promotes apoptosis in vivo.Fig. 5CYP2E1 overexpression induces LMP and cell apoptosis in vivo. (A-B). The expression levels of CYP2E1, LAMP1, LAMP2, CTSD, NEU4 and Cleaved Caspase-3 in the liver tumors from the nude mice were assessed by Western blot analysis (A) and quantitatively analyzed (B). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0032 (CYP2E1), ***P = 0.0005 (NEU4); **P = 0.0097 (CTSD), **P = 0.0095 (Cleaved Caspase-3/Caspase-3 ratio). (C-D). Liver tumor tissue lysates were incubated with PNGase F at 37 °C for 2 h. The deglycosylated LAMP1 and LAMP2 were then analyzed by Western blot analysis (C), and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0096 (de-LAMP1), **P = 0.0098 (de-LAMP2). The data represent the mean ± SEM. (E-F). IHC staining for CYP2E1, LAMP1, LAMP2, CTSD and NUE4 (E) and IF staining for Gal-3 (F) in the samples derived from the tumors formed with the HepG2 cell variants were detected. Scale bar, 50 µm.Fig 5 dummy alt text CYP2E1 overexpression induces LMP and cell apoptosis in vivo. (A-B). The expression levels of CYP2E1, LAMP1, LAMP2, CTSD, NEU4 and Cleaved Caspase-3 in the liver tumors from the nude mice were assessed by Western blot analysis (A) and quantitatively analyzed (B). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0032 (CYP2E1), ***P = 0.0005 (NEU4); **P = 0.0097 (CTSD), **P = 0.0095 (Cleaved Caspase-3/Caspase-3 ratio). (C-D). Liver tumor tissue lysates were incubated with PNGase F at 37 °C for 2 h. The deglycosylated LAMP1 and LAMP2 were then analyzed by Western blot analysis (C), and quantitatively analyzed (D). HepG2/Vector vs. HepG2/CYP2E1 group: **P = 0.0096 (de-LAMP1), **P = 0.0098 (de-LAMP2). The data represent the mean ± SEM. (E-F). IHC staining for CYP2E1, LAMP1, LAMP2, CTSD and NUE4 (E) and IF staining for Gal-3 (F) in the samples derived from the tumors formed with the HepG2 cell variants were detected. Scale bar, 50 µm. Low CYP2E1 expression is negatively associated with LAMP1/2 in HCC patients Analysis of the TCGA-LIHC database revealed that LAMP1 and LAMP2 mRNA levels were up-regulated in primary HCC samples compared to normal tissues (Fig. 6A). We then examined the protein levels of CYP2E1 and LAMP1 and LAMP2 in the tumor tissues (T) and their paired adjacent normal tissues (N) from 30 HCC patients using Western blot analysis (Fig. 6B) and IHC staining (Fig. 6C). Compared with the adjacent non-tumor tissues, CYP2E1 expression was lower in 23 of 30 (76.7%) tumor specimens. In contrast, LAMP1 and LAMP2 levels were higher in 22 of 30 (73.3%) and 19 of 30 (63.3%) tumor samples, respectively. Additionally, 17 of 30 (56.7%) samples for LAMP1 and 16 of 30 (53.3%) samples for LAMP2 exhibited a band shift towards higher molecular weight, indicative of increased glycosylation. Furthermore, a negative correlation was observed between CYP2E1 expression and both LAMP1/2 expression and glycosylation (Fig. 6D–E). Together, these data suggest that downregulated CYP2E1, along with upregulated LAMP1/2 expression and glycosylation may contribute to HCC tumorigenesis.Fig. 6Low CYP2E1 expression is negatively associated with LAMP1/2 in HCC patients. (A). Comparison of the LAMP1 and LAMP2 mRNA level between HCC and normal tissues in TCGA database. Statistical significance was assessed using two-tailed Student’s t-test. (B-C). The expression levels of CYP2E1, LAMP1 and LAMP2 in the specimens of HCC tumor tissues (T) and adjacent non-tumor tissues (N) were assessed by Western blot analysis (B) and IHC staining (C). Scale bar, 50 µm. (D-E). Correlation analysis of CYP2E1 expression with LAMP1/2 expression (D) and LAMP1/2 glycosylation (E) in human HCC samples.Fig 6 dummy alt text Low CYP2E1 expression is negatively associated with LAMP1/2 in HCC patients. (A). Comparison of the LAMP1 and LAMP2 mRNA level between HCC and normal tissues in TCGA database. Statistical significance was assessed using two-tailed Student’s t-test. (B-C). The expression levels of CYP2E1, LAMP1 and LAMP2 in the specimens of HCC tumor tissues (T) and adjacent non-tumor tissues (N) were assessed by Western blot analysis (B) and IHC staining (C). Scale bar, 50 µm. (D-E). Correlation analysis of CYP2E1 expression with LAMP1/2 expression (D) and LAMP1/2 glycosylation (E) in human HCC samples. Discussion Although the pro-apoptotic effect of CYP2E1 overexpression in HCC is well documented [20], the underlying molecular mechanism remain poorly understood. Notably, HCC tumor tissues typically exhibit low CYP2E1 expression, and alter lysosomal morphology and function [9]. Our previous studies have shown that the CYP2E1 overexpression-induced inhibition of HCC cell growth is related to autophagy inhibition [6], a process closely linked to lysosomal dysfunction [21]. In the present study, we investigated the relationship between CYP2E1 overexpression-induced apoptosis and lysosomal dysfunction in HCC. We found that CYP2E1 overexpression induced LMP, resulting in the leakage of CTSD from the lysosomal lumen to the cytoplasm and subsequent CTSD-dependent apoptosis in HCC cells. Mechanistically, CYP2E1 overexpression upregulated sialidase NEU4 expression, which induced the deglycosylation and degradation of LAMP1/2, eventually led to LMP and cell apoptosis. Clinically, downregulated CYP2E1 level in HCC patients strongly correlated with high expression and glycosylation of LAMP1/2. Thus, LMP represents a novel mechanism in CYP2E1-induced apoptosis in HCC cells, which may open innovative avenues for the development of CYP2E1-based oncolytic agents. CYP2E1 that is mainly expressed in the liver mediates the metabolic activation of numerous procarcinogens and is known as a key hepatic metabolic enzyme involved in HCC tumorigenesis [22]. Studies have demonstrated that CYP2E1 is highly expressed in normal and cirrhotic tissues, but is significantly downregulated in HCC tissues[7]. Low CYP2E1 expression is often associated with aggressiveness and poor prognosis of the HCC patients [9]. Similarly, in vivo studies have showed that the level of CYP2E1 expression gradually declined during the development of liver lesion and cirrhosis, and becoming nearly undetectable in the HCC advanced stages [8]. Although the expression pattern of CYP2E1 in HCC has been well documented, its function and underlying mechanism in development of HCC are still unclear. Our previous studies reported that tumor-suppressive effect of CYP2E1 in HCC development was linked to autophagy inhibition [6], which often results from lysosomal dysfunction, such as LMP and loss of acidic pH. As a key generator of ROS [23], CYP2E1 promotes ROS accumulation that directly damages the lysosomal membrane, catalyzes Fe2+ within the lysosomal lumen via the Fenton reaction, and produces highly oxidizing hydroxyl radicals that ultimately lead to LMP [24]. Conversely, ROS scavenging could relieve LMP and autophagy defects [25,26]. However, direct evidence establishing a causal relationship between CYP2E1 and lysosomal dysfunction has not been established. Here, we found that CYP2E1-induced LMP specifically activates the CTSD-dependent apoptotic cascade. LMP leads to the release of lysosomal cathepsins into the cytosol, initiating multiple programmed cell death pathways including apoptosis, pyroptosis, and ferroptosis[27]. Cathepsins are lysosomal enzymes that contribute to protein degradation and their release often leads to cell apoptosis [28], accompanied by the activation of apoptotic proteases and degradation of antiapoptotic proteins [[29], [30], [31]]. Notably, cathepsins, particularly cathepsins B and D, play pivotal roles in cleaving Bid and inducing mitochondrial outer membrane permeabilization (MOMP) [32]. Additionally, cathepsins are responsible for the degradation of the antiapoptotic protein BCL-2 and the activation of BAX and BAK [27]. Consistently, we observed that treatment with CTSD inhibitor Pep A significantly attenuated CYP2E1 overexpression-induced LMP and apoptosis, confirming the critical role of CTSD in this process. Lysosome-associated membrane proteins 1 and 2 (LAMP1/2) are highly glycosylated transmembrane proteins that are ubiquitously expressed in the lysosomal membrane and play a critical role in maintaining its integrity [33]. Compared with non-cancerous regions, the expression levels of LAMP1/2 are significantly upregulated in HCC, suggesting an increase in the number of lysosomes in cancerous regions [34]. It has been reported that increased LAMP1 expression correlates with enhanced metastatic potential of cancers by increased cellular spreading and motility on fibronectin and Matrigel, whereas its downregulation inhibits metastasis [35]. In this study, Western blot analysis showed that higher expression levels of LAMP1/2 were detected in 22 of 30 (73.3%) and 19 of 30 (63.3%) HCC tumor specimens respectively, compared with the paired non-tumor tissues, supporting their involvement in HCC tumorigenesis. In addition, LAMP1 is a major carrier of poly-N-acetyllactosamine (polyLacNAc)-substituted β1,6 branched N-glycans [36,37], which facilitate metastasis in high-metastasis variants of lung colonizing B16 murine melanoma cells (B16F10) [35]. However, overexpression of LAMP1 alone in low-metastatic B16F1 cells, which lack the whole glycosylation machinery, fails to affect spreading and motility until the cells were provided with proper glycosylation [35], suggesting that adequate glycosylation of LAMP1 is required for its metastatic function. In our study, high LAMP1/2 expression and glycosylation in HCC tissues were observed and were negatively associated with low CYP2E1 expression. This pattern suggests that during HCC progression, reduced CYP2E1 may permit excessive LAMP1/2 glycosylation and stabilization, thereby protecting cancer cells from LMP-induced apoptosis. Conversely, restoring CYP2E1 expression or pharmacologically inducing LMP could represent a novel therapeutic strategy for HCC. Both in vitro and in vivo, we found that CYP2E1 overexpression not only decreased the protein levels of LAMP1/2 but also increased their deglycosylation. These findings indicate that CYP2E1 overexpression-induced deglycosylation of LAMP1/2 results in lysosomal membrane instability, which sensitizes cells to LMP. In addition, CYP2E1 overexpression enhanced post-transcriptional degradation of LAMP1/2. Since the highly glycosylated luminal domain protects the LAMPs from degradation, it is reasonable to speculate that deglycosylation of LAMP1/2 is the reason for their degradation. PNGase F digestion assays further suggested that CYP2E1-induced deglycosylation of LAMP1/2 is involved in regulation of LAMP1/2 degradation. LMP is often associated with the degradation of LAMP1/2 [38]. Oncogenes-induced degradation of these proteins sensitizes the human breast and colon carcinoma cells to photo-oxidation-induced LMP [38]. In this study, using a CTSD inhibitor, we demonstrated that CYP2E1-induced protein degradation of LAMP1/2 depends on CTSD activity. This increased degradation of LAMP1/2 was attributed to the release or increased expression of the CTSD in the cytosol. Together, these findings suggest that CYP2E1 overexpression induces deglycosylation of LAMP1/2, followed by CTSD-mediated degradation, ultimately leading to LMP. Neuraminidase 4 (NEU4) is a sialidase responsible for removing sialic acids (SAs) residues from glycoconjugates including glycoproteins and glycolipids[39]. In HCC tissues, NEU4 expression is often downregulated, and its reduced levels correlate with higher tumor grades and poor prognosis [19]. This downregulation of NEU4 is also associated with the upregulated SAs levels in HCC tissues [19]. Functionally, NEU4 expression suppresses migration and invasion of HCC cells, an effect related to its desialylation of highly glycosylated membrane protein CD44, which promotes cell motility [19]. Conversely, reducing NEU4 expression restores the migratory ability of HCC cells [19]. Proper sialylation of LAMPs is known to support lysosomal function and their stability while desialylation increases their susceptibility to degradation [40,41]. Given the importance of sialylation modification in maintaining LAMPs stability, we examined the expression levels of NEU4 in the HCC/Vector and the HCC/CYP2E1 cells. We found that NEU4 expression was increased in the CYP2E1-overexpressing cells. Importantly, knockdown of NEU4 effectively rescued the deglycosylation of LAMP1/2, and attenuated LMP and apoptosis in the HCC/CYP2E1 cells. In general, there are several limitations in our study that need to be further investigated. First, our study focused primarily on apoptosis and lysosomal dysfunction; however, emerging evidence suggests that other forms of organelle membrane permeabilization, particularly mitochondrial dysfunction play critical roles in PANoptosis [26,42] which is closely associated with LMP. Moreover, the potential crosstalk between lysosomal dysfunction and other cell death mechanisms, such as ferroptosis or necroptosis, which may also contribute to the anti-tumor effects of CYP2E1 overexpression, remains unexplored. Future studies are warranted to address these questions. Second, our clinical sample analysis was limited by a relatively modest sample size, which may limit the statistical power and generalizability of our findings. Therefore, larger cohort studies with comprehensive clinicopathological data are necessary to further validate the clinical significance of the CYP2E1-NEU4-LAMP axis. Finally, the long-term safety and efficacy of targeting the CYP2E1-NEU4-LAMP axis remain to be evaluated in more clinically relevant animal models. Conclusion Our study demonstrates that CYP2E1 overexpression increased the sialidase NEU4 expression, leading to deglycosylation of LAMP1/2, and their subsequent degradation by CTSD, thereby inducing LMP. CYP2E1-induced LMP further results in cell apoptosis in vitro and in vivo. Clinically, decreased CYP2E1 expression in HCC tissue is strongly associated with high glycosylation of LAMP1/2. Thus, here we provide a novel mechanism underlying CYP2E1 function in HCC tumorigenesis. Enhancing CYP2E1-mediated LMP, whether by restoring CYP2E1 expression or pharmacologically targeting the NEU4-LAMP axis, may represent a novel and promising therapeutic strategy for HCC treatment. Abbreviations CYP2E1Cytochrome P450 2E1HCCHepatocellular carcinomaLMPLysosomal membrane permeabilizationLAMP1Lysosome-associated membrane protein 1LAMP2Lysosome-associated membrane protein 2CTSDCathepsin DNEU4Neuraminidase 4LDCDLysosome-dependent cell deathROSReactive oxygen speciesCHXCycloheximidePep APepstatin ASAsSialic acids CYP2E1Cytochrome P450 2E1HCCHepatocellular carcinomaLMPLysosomal membrane permeabilizationLAMP1Lysosome-associated membrane protein 1LAMP2Lysosome-associated membrane protein 2CTSDCathepsin DNEU4Neuraminidase 4LDCDLysosome-dependent cell deathROSReactive oxygen speciesCHXCycloheximidePep APepstatin ASAsSialic acids Ethics statement All human samples approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (2019 IEC (S646)). All animal-experimental approved by the Ethics Committee of Jianghan University (JHDXLL2024–005). Funding sources This work was supported by the 10.13039/501100001809National Natural Science Foundation of China (Grant No. 81872040), the research project of the Wuhan Municipal Committee of the China Democratic League (Grant No WHMJ25LH23) and the Research Fund of Jianghan University (Grant No.2021jczx-002). CRediT authorship contribution statement Xuan Wang: Writing – original draft, Software, Methodology, Investigation, Data curation. An Wang: Writing – original draft, Methodology, Investigation, Data curation. Huanhuan He: Writing – original draft, Methodology, Investigation, Data curation. Jiaqi Qiao: Methodology, Investigation. Chengyi Wang: Methodology, Investigation. Haiyuan Du: Methodology, Investigation. Xiji Shu: Writing – review & editing, Supervision. Binlian Sun: Writing – review & editing, Supervision. Xiaoqing Chen: Resources, Methodology. Qiongxia Chen: Resources, Methodology. Xuan Huang: Resources, Methodology. Shaobo Hu: Writing – review & editing, Supervision, Conceptualization. Yuchen Liu: Writing – review & editing, Supervision, Funding acquisition, Conceptualization. Zhengqi Fu: Writing – review & editing, Supervision, Funding acquisition. Declaration of competing interest The authors declare that they have no competing interests.